The 2021 study by Khojandi et al. found that in a cohort of 129 melanoma patients treated with anti-CTLA-4 (ipilimumab) a BMI ≥ 30kg/m2 at treatment initiation was associated with better OS (p = 0.0368) (Table 1) but had no effect on PFS (30). This evidence concerns the gene CTLA4 and melanoma.